COMMUNIQUÉS West-GlobeNewswire

ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction
22/05/2026
LOS ANGELES, May 22, 2026 (GLOBE NEWSWIRE) -- ANGEL, a global water purification brand, has introduced the X2 Tankless RO Water Filter System, a compact under-sink solution designed to deliver fresh purified water while [...]
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute
22/05/2026
Les résultats de Topline seront présentés par le Pr Alexandra Leary, PhD, le 30 mai 2026 au congrès annuel de l’ American Society of Clinical Oncology (ASCO) à Chicago OSE Immunotherapeutics organisera un webcast avec [...]
Ex dividend NOK 1.00 today
22/05/2026
The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.00 as from today, 22.05.2026.
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
22/05/2026
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026, at the 2026 Annual [...]
CROSSJCROSSJECT annonce le succès d’une augmentation de capital et d’une émission de bons de souscription d’actions (BSA) au profit d’investisseurs pour un montant de 15 millions d’euros
22/05/2026
Nouveaux financements immédiats pour soutenir les prochaines étapes stratégiques de la Société Renforcement des capitaux propres et amélioration de la structure financière de la Société Soutient de la poursuite des [...]
CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
22/05/2026
Provides immediate new financing to support the Company’s next strategic milestones Strengthens shareholders’ equity and improves the Company’s financial structure Supports the continuation of ZEPIZURE® regulatory [...]
FemiCore Claims Evaluated: Investigating the Ingredients for Bladder Support - Femi Core Consumer Complaints Exposed
22/05/2026
FemiCore Ingredients Explained: Mimosa Pudica, Cranberry, Bearberry, Berberine, and 5-Strain Lactobacillus Probiotic Blend for Women's Bladder Support in 2026 Tallmadge, Ohio, May 21, 2026 (GLOBE NEWSWIRE) -- These [...]
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
22/05/2026
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative [...]
Medline Inc. announces pricing of upsized secondary offering of Class A common stock
22/05/2026
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by [...]
Most Effective Magnesium Pain Cream Researched: Real Magnesium Niacinamide Relief for Peak Health & Nerve Pain Recovery
22/05/2026
How the Magnesium Chloride and Niacinamide Topical Cream with Arnica, Boswellia, Menthol, and Camphor Supports Joint, Nerve, and Muscle Comfort Routines SPEARFISH, SD, May 21, 2026 (GLOBE NEWSWIRE) -- These statements [...]
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study
22/05/2026
Last Patient In enrolled ahead of schedule; interim analysis anticipated by year-end 2026 to inform plans for the next stage of development TAIPEI, May 21, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) today [...]
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
22/05/2026
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 [...]
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
22/05/2026
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 [...]
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
22/05/2026
ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the [...]
Liminatus Pharma Announces Nasdaq Delisting Notification
22/05/2026
FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“ [...]
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
22/05/2026
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows [...]
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
22/05/2026
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered [...]
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
21/05/2026
Presentations to cover progress across Eikon’s most advanced clinical-stage programs Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer (“NSCLC [...]
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
21/05/2026
Preliminary mPFS of 15.2 months; mDOR not reached Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases ORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACC Dose [...]

Pages